BMS 986165

Drug Profile

BMS 986165

Alternative Names: BMS-986165

Latest Information Update: 20 Jul 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antipsoriatics
  • Mechanism of Action TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Plaque psoriasis
  • Phase I Autoimmune disorders; Psoriasis
  • Preclinical Inflammatory bowel diseases; Systemic lupus erythematosus

Most Recent Events

  • 14 Jun 2017 Adverse events and pharmacokinetics data from a phase I trial in Plaque psoriasis presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 27 Mar 2017 Bristol-Myers Squibb completes a phase I trial in Autoimmune disorders (In volunteers) in USA (PO) (NCT03044873)
  • 07 Feb 2017 Phase-I clinical trials in Autoimmune disorders (In volunteers) in USA (PO) (NCT03044873)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top